Eight months into 2022, it’s fair to say that it’s been a tepid year of deal-making in the biotechnology industry, and that’s one reason why the related stocks and exchange traded funds are scuffling. Still, hope burns eternal, with some market observers speculating that biotech consolidation is poised to ramp up, potentially benefiting ETFs such [...] The post Consolidation Case for Biotech ETF BBH appeared first on ETF Trends .